Armata Pharmaceuticals Highlights AP-SA02 Data at ISSSI 2026
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
phage therapy
Advertisement
SNIPR Advances SNIPR001 Into Phase 2 for E. coli Prevention
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
Bright Path Labs Receives FDA AMT Designation for Medicines
Mesa, Arizona, U.S., September 14, 2026 Bright Path Labs, a U.S.-based pharmaceutical manufacturer, announced that the U.S. Food and...
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Intelligent Bio Solutions Completes Clinical Study for FDA 510(k) Submission
NEW YORK, August 11, 2026 Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for...
Advertisements
SNIPR Advances SNIPR001 With Compassionate-Use Clinical Evidence
COPENHAGEN, Denmark, August 12, 2026 SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced...
Armata Secures $2.5M DoD Funding for AP-SA02
LOS ANGELES, Calif. | June 23, 2026 Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from...
Armata Pharmaceuticals Launches Advanced cGMP Phage Plant
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Advertisement
